Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.

Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.

Publication date: Mar 02, 2019

Efficacy and safety profiles of alemtuzumab for relapsing-remitting multiple sclerosis (RRMS) mainly come from Western countries and have not been reported in Asian populations. The aim of this study was to report the efficacy and safety of alemtuzumab for RRMS patients in a Korean population.

We retrospectively reviewed RRMS patients treated with alemtuzumab. Study outcomes included annualized relapse rate (ARR), expanded disability status scale (EDSS) score, 6-month confirmed disability worsening (CDW), confirmed disability improvement (CDI), MRI lesion activity (new/enlarging T2 hyperintense and gadolinium-enhancing T1 lesions), no evidence of disease activity (NEDA), and adverse events.

Nineteen patients were identified and mean follow-up was 1.5 years after alemtuzumab initiation. Mean ARR fell from 1.20 pre-treatment to 0.30 post-treatment (p

Kim, H., Lee, E.J., Kim, S.K., Kim, K.K., and Lim, Y.M. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients. 17510. 2019 Mult Scler Relat Disord (30):

Concepts Keywords
Alemtuzumab MRI
Asian Health
Disability Autoimmune diseases
Gadolinium Clinical medicine
Lesion Relapsing–remitting
MRI EDSS
Multiple Sclerosis Sanofi
Relapse Alemtuzumab
Multiple sclerosis

Semantics

Type Source Name
gene UNIPROT SLC35G1
drug DRUGBANK Gadolinium
gene UNIPROT CYREN
disease MESH relapse
gene UNIPROT DNMT1
gene UNIPROT CD69
gene UNIPROT CD5L
disease DOID relapsing-remitting multiple sclerosis
disease MESH relapsing-remitting multiple sclerosis
disease DOID multiple sclerosis
disease MESH multiple sclerosis
drug DRUGBANK Alemtuzumab

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *